ArticleJTO clinical and research reports2022

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC.

Gillianne G Y Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.